Opko Health, Inc. key statistics and ratios
In fiscal 2025, Opko Health, Inc. had return on equity of -17.1%, an operating margin of -19.3%, debt equal to 27.1% of equity and a current ratio of 3.97. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 34.9% | 52.6% | 38.4% | 40.7% | 89.2% | 89.7% | 60.7% | 49.5% | — | — | — | — | — | 28.7% | 36.8% | 30.6% | 33.9% | 40.8% |
| Operating margin | −501.3% | −39.1% | −82.9% | −79.2% | −82.5% | −160.0% | −20.0% | −8.6% | −28.6% | −17.3% | −30.4% | 4.0% | 1.1% | −22.5% | −18.2% | −21.3% | −19.3% | −8.2% |
| Net margin | −681.6% | −66.4% | −4.6% | −61.7% | −118.5% | −188.4% | −6.1% | −4.3% | −31.6% | −15.5% | −34.9% | 2.1% | −1.7% | −32.7% | −21.9% | −7.5% | −37.2% | −12.4% |
| Free-cash-flow margin | −533.7% | −68.4% | −73.1% | −57.2% | −61.8% | −104.4% | 31.2% | 1.2% | −14.3% | −13.8% | −20.5% | 0.4% | 0.3% | −11.9% | −5.2% | −29.2% | −31.4% | −22.8% |
| Return on equity | −95.3% | −69.3% | −1.4% | −17.1% | −21.7% | −20.0% | −2.1% | −2.4% | −15.7% | −8.4% | −18.5% | 1.9% | −1.8% | −20.2% | −12.8% | −3.9% | −17.1% | −5.9% |
| Return on assets | — | −24.3% | −0.8% | −11.2% | −13.6% | −12.9% | −1.5% | −1.7% | −11.4% | −6.1% | −13.2% | 1.3% | −1.2% | −14.4% | −9.0% | −2.5% | −10.9% | −3.9% |
| Asset turnover | — | 0.37 | 0.18 | 0.18 | 0.11 | 0.07 | 0.24 | 0.40 | 0.36 | 0.39 | 0.38 | 0.60 | 0.73 | 0.44 | 0.41 | 0.34 | 0.29 | 0.31 |
| Current ratio | — | 2.08 | 5.30 | 1.50 | 2.64 | 1.72 | 1.80 | 1.84 | 1.12 | 1.10 | 1.30 | 1.39 | 2.49 | 1.85 | 1.55 | 3.43 | 3.97 | 3.35 |
| Debt to equity | 0.0% | 127.5% | 10.9% | 21.1% | 25.6% | 17.2% | 4.2% | 2.7% | 6.9% | 8.0% | 17.3% | 16.5% | 13.1% | 18.6% | 15.6% | 44.7% | 27.1% | 29.5% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | — | — | — | — | — | — | — | — | — | 1.0x | n/m | n/m | n/m | — | — |
| Effective tax rate | — | — | — | — | — | — | — | — | — | — | — | 36.2% | — | — | — | — | — | — |
| R&D as % of revenue | 245.3% | 20.9% | 40.6% | 41.5% | 55.8% | 91.7% | 20.2% | 10.2% | 13.1% | 12.7% | 13.1% | 5.2% | 4.3% | 7.4% | 10.4% | 14.8% | 20.4% | 21.3% |
| SG&A as % of revenue | 234.8% | 63.6% | 68.5% | 59.1% | 57.3% | 63.6% | 40.0% | 36.5% | 42.9% | 36.2% | 38.1% | 24.8% | 26.4% | 37.1% | 34.8% | 42.7% | 36.7% | 35.0% |
| Capital spending as % of revenue | 2.8% | 2.7% | 7.0% | 3.1% | 4.1% | 5.2% | 2.2% | 1.7% | 4.8% | 2.8% | 1.4% | 2.3% | 1.8% | 2.4% | 1.9% | 3.5% | 2.0% | 1.8% |
| Free cash flow ÷ net income | — | — | — | — | — | — | — | — | — | — | — | 18.9% | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 23.1% | 46.1% | 28.4% | 31.5% | 32.9% | 43.1% | 36.8% | 48.9% |
| Operating margin | −38.7% | −18.0% | −44.8% | −38.3% | 31.7% | −25.8% | −41.1% | −4.3% |
| Net margin | 14.3% | 7.6% | −45.1% | −94.7% | 14.3% | −21.1% | −44.2% | −5.1% |
| Free-cash-flow margin | −49.0% | −27.1% | −25.2% | −55.3% | −24.9% | −19.3% | −17.0% | −28.4% |
| Current ratio | 2.97 | 3.43 | 2.49 | 3.41 | 3.70 | 3.97 | 3.61 | 3.35 |
| Debt to equity | 0.4% | 32.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% |
| R&D as % of revenue | 16.6% | 16.6% | 20.6% | 19.3% | 19.8% | 22.1% | 23.5% | 20.3% |
| SG&A as % of revenue | 56.6% | 36.5% | 39.4% | 38.0% | 35.5% | 34.0% | 39.1% | 32.4% |
Financial health
- Short-term assets cover short-term liabilities $500m of assets due within a year against $149m of liabilities due within a year.
- Short-term assets cover long-term liabilities $500m short-term assets against $496m of longer-dated liabilities.
- More cash than debt $301m of cash against $3m of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 12% to 0% over five years.
- A year's operating cash flow covers at least 20% of debt −$123m of operating cash flow against $3m of debt.
- Operating profit covers interest at least five times over Operating income of −$48m against −$63m of interest.
Moat
Weak moat
How hard Opko Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -8.8% of total assets over 10 years.
- Durability 10 / 20
Operating margin has been a median -18.1%; its worst year was -37.2%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 10 years, at a median -13.4% of revenue.
- Discipline 10 / 20
The diluted share count rose 22.8% over five years; stock-based pay has been a median 1.6% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (26 before it).
Compare with peers
- Alvotech statistics
- Emergent Biosolutions Inc. statistics
- Travere Therapeutics, Inc. statistics
- Amphastar Pharmaceuticals, Inc. statistics
- Pacira Biosciences, Inc. statistics
Head to head: ALVO vs OPKEBS vs OPKOPK vs TVTX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies